1.1. Ludwig H, Van Bells S, Barret-Lee P et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293-306.2.2. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue.3.3. Teicher BA, Holden SA, al-Achi A et al. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 1990; 50: 3339-44.4.4. Beverly A, Teicher BA, Dupuis N et al. Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiation Oncol Investigat 1994; 2 (6): 269-76.5.5. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1 is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998; 95: 7987-92.6.6. Larcher F, Murillas R, Bolontrade M et al. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 1998; 17: 303-11.7.7. Caro JJ, Salas M, Ward A et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91: 2214-21.8.8. Groopman JE, Itri LM. Chemotherapy induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91: 1616-34.9.9. Dührsen U, Augener W, Zwingers T, Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol 1987; 67 (2): 235-9.10.10. De Rienzo DP, Saleem A. Anemia of chronic disease: a review of pathogenesis. Tex Med 1990; 86: 80-3.11.11. Moldawer LL, Marano MA, Wei H et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J 1989; 3: 1637-43.12.12. Johnson JY, Waddelow TA, Caro J et al. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 1989; 74: 130-8.13.13. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-10.14.14. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000; 275: 19 906-12.15.15. Singh PK, Parsek MR, Greenberg EP, Welsh MJ. A component of innate immunity prevents bacterial biofilm development. Nature 2002; 417: 552-5.16.16. Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995; 95 (4): 1650-9.17.17. Jacobs K et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985; 313: 806-10.18.18. Miller CB, Jones RJ, Piantadosi S et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322: 1689-92.19.19. Smyth J, Boogaerts M, Ehmer B. Erythropoietin in cancer supportive treatment. NY: Marcel Dekker Inc. 1996; p. 13-34.20.20. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006; 25 (1).21.21. Nishii K et al. Successful treatment of aplastic anemia with G-CSF and high dose erythropoietin. Leuk Lymphoma 1998; 30: 211-4.22.22. Agency for Healthcare Research and Quality 2006.23.23. http://www.aranesp.com24.24. Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299 (8): 914-24.25.25. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, doubleblind, placebo-controlled trial. Lancet 2003; 362 (9392): 1255-60.26.26. Overgaard J, Hoff C, Sand Hansen H et al. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): the Danish Head and Neck Cancer Group DAHANCA 10 rand [abstr.]. Eur J Cancer Suppl 2007; 5 (6): 7.27.27. Bolhius J, Schmidlin K, Brillantet C et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373: 1532-42.28.28. Delarue R, Haioun C, Coiffier B et al. Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immuno chemotherapy: The LNH03-6B study. J Clin Oncol 2011; 29 (abstr. 9048).29.29. Nitz U, Gluz O, Oberhoff C. Reimer adjuvant chemotherapy with or without darbepoetin alpha in node-positive breast cancer: survival and quality of life analysis from the prospective randomized WSg ara plus trial.30.30. Rizzo JD, Brouwers M, Hurley P et al. American Society of Clinical Oncology-American Society of Hematology. Clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with Cancer J of Clin Oncol 2010; 28 (33): 4996-5010.31.31. Henry DH, Dahl NV, Auerbach M et al. Intravenous ferric gluconate improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12: 231-42.32.32. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open label, randomized trial. J Clin Oncol 2004; 22: 1301-7.33.33. Hedenus M, Birgegard G, Nasman P et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007; 21: 627-32.34.34. Bastit L, Vandebroek A, Altintas S et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008; 26: 1611-8.35.35. Pedrazzoli P, Farris A, Del Prete S et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alfa. J Clin Oncol 2008; 26: 1619-25.36.36. Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol 2004; 76 (1): 74-8.